Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate.
We investigated the correlation between whole blood gold concentrations and clinical outcomes in 59 auranofin-treated patients and 51 gold sodium thiomalate-treated patients who completed a 21-week, placebo-controlled, multicenter parallel trial. Whole blood gold concentrations did not correlate with clinical outcome, as assessed by changes in joint tenderness, joint swelling, or Westergren erythrocyte sedimentation rate. They also did not correlate with toxic reactions necessitating withdrawal from the study.
D000293:Adolescent; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006046:Gold / Q000031:analogs & derivatives* / Q000097:blood*; D006052:Gold Sodium Thiomalate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007596:Joints / Q000473:pathology; D010919:Placebos
D010919:Placebos; D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold